Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 5/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12440624 | 0.85 | RORC (0.37) | RORCDRD2MEN1MAPK1KMT2A | |
| SCHEMBL2087734 | 0.84 | RORC (0.43) | RORCMEN1MAPK1KMT2ACTSK | |
| SCHEMBL14805858 | 0.83 | MEN1 (0.36) | RORCDRD2MEN1MAPK1KMT2A | |
| SCHEMBL1994522 | 0.82 | USP2 (0.47) | EPHX2 | |
| SCHEMBL20975988 | 0.82 | DRD2 (0.40) | RORCDRD2MEN1MAPK1KMT2A | |
| SCHEMBL21410530 | 0.82 | RORC (0.38) | RORCDRD2MEN1MAPK1KMT2A | |
| SCHEMBL16887631 | 0.82 | CYP4F2 (0.40) | RORCMEN1MAPK1KMT2ARET | |
| SCHEMBL20328214 | 0.81 | DRD2 (0.39) | RORCDRD2MEN1KMT2ARET | |
| SCHEMBL25985026 | 0.81 | RORC (0.35) | RORCDRD2MEN1MAPK1KMT2A | |
| SCHEMBL18705060 | 0.81 | HRH3 (0.40) | RORCMEN1MAPK1KMT2ARET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111410662-B | Tyrosine kinase inhibitor | 苏州信诺维医药科技有限公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-111410662-A | Tyrosine kinase inhibitor | 苏州信诺维医药科技有限公司 | 2020-07-14 | — | — | CN | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RORC 440/4885DRD2 3425/4885MEN1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.